Status:
COMPLETED
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer
Lead Sponsor:
Gemin X
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogneic signal is present. Obatoclax is designed to restore apoptosis through inhibition ...
Eligibility Criteria
Inclusion
- Pathological confirmation of Non-Small Cell Lung Cancer (NSCLC)
- Must have been previously treated with a single platinum-based chemotherapy regimen and shown evidence of disease progression; no further limitations
- Must have normal organ function
- Must be willing to submit to blood sampling for planned PK and PD analysis
- Must have the ability to understand and willingness to sign a written informed consent form
Exclusion
- No other agents or therapies administered with the intent to treat malignancy
- Patients with prior exposure to obatoclax or docetaxel
- Uncontrolled, intercurrent illness
- Pregnant women and women who are breast feeding
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT00405951
Start Date
October 1 2006
End Date
September 1 2009
Last Update
July 21 2016
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic College of Medicine
Scottsdale, Arizona, United States, 85259
2
Tower Oncology
Beverly Hills, California, United States, 90210
3
Georgetown University
Washington D.C., District of Columbia, United States, 20007
4
H. Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612